Finally, given the previous report that paricalcitol induces KDM6B expression in CRC and breast cancer cells, we investigated the combination of paricalcitol and an anti-PD-L1 antibody for CRC therapy. The gene discussed is KDM6B; the disease is colorectal carcinoma.